Active secondary progressive multiple sclerosis treatment with a selective sphingosine-1-phosphate receptor modulator

Czech version

Authors: Ing. Kateřina Michnová ¹; doc. MUDr. Dana Horáková, Ph.D. ²
Authors‘ workplace: šéfredaktorka, Care Comm s. r. o. ¹; Neurologická klinika 1. LF UK a VFN v Praze ²
Published in: Cesk Slov Neurol N 2020; 83/116(6): 683-684
Category: Drug Profile

Sources

1. SPC přípravku Mayzent. [online]. Dostupné z URL: https: //www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_cs.pdf

2. Behrangi N, Fischbach F, Kipp M et al. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells 2019; 8 (1): 24. doi: 10.3390/cells8010024.

3. Kappos L, Bar-Or A, Cree BA et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391 (10127): 1263–11273. doi: 10.1016/S0140-6736 (18) 30475-6.

4. Steiner D, Arnold D, Freedman M et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): Results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial [abstract]. Neurology 2016; 86 (Suppl): E22.

5. ClinicalTrials.gov. A clinical study of the efficacy of Natalizumab on reducing disability progression in participants with secondary progressive multiple sclerosis (ASCEND in SPMS). [online]. Available from URL: https: //clinicaltrials.gov/ct2/show/results/NCT01416181.

6. Kappos L, Weinshenker B, Pozzilli C et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63 (10): 1779–1787. doi: 10.1212/01.wnl.0000145561.08973.4f.

7. Panitch H, Miller A, Paty D et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63 (10): 1788–1795. doi: 10.1212/01.wnl.0000146958.77317.3e.

8. Kappos L, Polman C, Pozzilli C et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57 (11): 1969–1975. doi: 10.1212/wnl.57.11.1969.

9. Benedict RH, Cree B, Tomic D et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: Results from phase 3 EXPAND Study [abstract]. Neurology 2018; 90 (15 Suppl): S44.004.

10. Benedict RH, Cree B, Tomic D et al. Siponimod improves cognitive processing speed in patients with SPMS: Results from Phase 3 EXPAND Study. [abstract]. Eur J Neurol 2018; 25 (Suppl 2) : 277–573. doi: 10.1111/ene.13700.

11. Gold R, Kappos L, Bar-Or A et al. Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis [abstract]. Mult Scler J 2019; 25 (2 Suppl) : 357–580. doi: 10.1177/1352458519868080.